Why the study?
Do statins improve periprocedural biomarkers and clinical outcomes in elderly patients (aged ≥ 75 years) with ACS and low LDL-C undergoing PCI?
Do statins improve periprocedural biomarkers and clinical outcomes in elderly patients (aged ≥ 75 years) with ACS and low LDL-C undergoing PCI?
Answers are grounded in this paper and cite their sources.
Statin therapy prior to PCI in elderly patients (≥75 years) with ACS and low LDL-C is associated with reduced periprocedural myocardial injury and lower 1-year MACE.
The effect of statins in patients with acute coronary syndrome (ACS) at advanced age with lower low-density lipoprotein cholesterol (LDL-C) levels undergoing percutaneous coronary intervention (PCI) remains unknown. We evaluated the effect of statins in 220 Chinese patients with ACS aged ≥ 75 years with low LDL-C undergoing PCI. Biomarkers were measured before and 6 hours after PCI, and patients were followed up for 1 year. Biomarkers in the statin group at 6 hours post-PCI were lower than controls (creatine kinase-myocardial band 14.2 ± 5.78 vs 47.3 ± 16.4 IU/L, P = .03; cardiac troponin I 0.36 ± 0.12 vs 1.33 ± 0.47 ng/mL, P = .01; and high-sensitivity C-reactive protein 7.6 ± 4.3 vs 13.6 ± 4.5 mg/L, P = .001, respectively). Significant differences were found in major adverse cardiac events at 1 year (P = .02-.01), while target lesion revascularization alone was less at 3 months between the 2 groups (P = .03). This study demonstrates that elderly patients with ACS having low LDL-C benefit from statins regardless of type, dosage, and duration of statin administration prior to PCI.
No takes yet. Share an insight, caveat, or question.
Congya et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: